The U.S. Food and Drug Administration announced six additional awardees under the Commissioner’s National Priority Voucher pilot program. “This second cohort brings the total number of voucher recipients to 15, underscoring the agency’s commitment to accelerating the review of products with the potential to address key national priorities,” the FDA stated. The following products were selected following external applications and internal nominations from FDA review divisions: Boehringer Ingelheim’s Zongertinib for HER2 lung cancer; Johnson & Johnson’s (JNJ) Bedaquiline for drug-resistant tuberculosis in young children; GlaxoSmithKline’s (GSK) Dostarlimab for rectal cancer; Casgevy for sickle cell disease, which is manufactured by Vertex Pharmaceuticals (VRTX) in collaboration with CRISPR Therapeutics (CRSP); Eli Lilly’s (LLY) Orforglipron for obesity and related health conditions; and Novo Nordisk’s (NVO) Wegovy for obesity and related health conditions.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Cathie Wood Pours into Veracyte Stake ahead of Earnings Beat, Slashes Biotech Holdings
- CRSP, BEAM, ROKU, SOFI: Cathie Wood Pours $17 Million into Biotech Stocks, Trims Tech Favorites
- FDA to speed up gene editing therapy approvals, Bloomberg reports
- Crispr Therapeutics’ Long-term Study on CAR T Therapies: A Market Game Changer?
- Video: This stock is dragging down the in vivo gene editing therapy space